The FDA has accepted a biologics license application for Genentech’s Port Delivery System with ranibizumab for the treatment of wet age-related macular degeneration, according to a press release.
The Port Delivery System (PDS), a permanent refillable eye implant, is designed to continuously deliver ranibizumab over several months. The application is supported by data from the phase 3 Archway study, which found that 98% of patients receiving medication through the system were able to go 6 months without additional treatment before refill, the release said. Vision outcomes were similar to